Loading...
XSHE002422
Market cap6.71bUSD
Dec 25, Last price  
30.83CNY
1D
1.72%
1Q
9.44%
Jan 2017
91.25%
IPO
-13.64%
Name

Sichuan Kelun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002422 chart
P/E
19.93
P/S
2.28
EPS
1.55
Div Yield, %
2.30%
Shrs. gr., 5y
1.60%
Rev. gr., 5y
5.58%
Revenues
21.45b
+13.44%
2,029,326,5502,621,391,2863,245,985,3454,026,399,9585,147,848,7585,885,278,6176,831,281,9818,023,421,2897,763,339,9828,565,943,41511,434,948,84116,351,790,23917,636,267,04416,464,201,27717,277,407,53318,912,653,46321,453,929,237
Net income
2.46b
+44.03%
216,288,383309,887,206427,851,436661,229,249966,126,0951,087,515,7481,079,521,5861,001,902,613645,271,323584,638,829748,544,1871,212,944,249937,855,128829,386,336868,116,5331,705,324,0672,456,112,045
CFO
5.34b
+70.65%
168,423,194221,075,877250,688,633149,292,039342,931,058402,771,4671,050,373,8451,218,735,9381,239,429,4361,725,407,4151,102,520,8282,953,506,9672,216,737,6392,219,381,5192,847,118,4283,127,457,0905,337,068,931
Dividend
May 29, 20240.8 CNY/sh

Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers IV solutions; injectable powder and small volume parenteral; oral preparation; intermediates and APIs; and peritoneal dialysis solutions. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
URL
https://www.kelun.com/
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
21,453,929
13.44%
18,912,653
9.46%
17,277,408
4.94%
Cost of revenue
17,070,315
15,751,923
14,739,049
Unusual Expense (Income)
NOPBT
4,383,614
3,160,730
2,538,358
NOPBT Margin
20.43%
16.71%
14.69%
Operating Taxes
933,787
364,002
309,499
Tax Rate
21.30%
11.52%
12.19%
NOPAT
3,449,827
2,796,728
2,228,859
Net income
2,456,112
44.03%
1,705,324
96.44%
868,117
4.67%
Dividends
(1,126,708)
(597,780)
(450,046)
Dividend yield
2.51%
1.51%
1.68%
Proceeds from repurchase of equity
13,882
(106,457)
BB yield
-0.03%
0.27%
Debt
Debt current
4,205,128
5,319,441
6,578,179
Long-term debt
3,139,040
4,762,469
3,538,214
Deferred revenue
288,206
208,884
225,728
Other long-term liabilities
78
Net debt
(3,593,932)
1,549,149
3,788,058
Cash flow
Cash from operating activities
5,337,069
3,127,457
2,847,118
CAPEX
(1,769,185)
(896,022)
(990,564)
Cash from investing activities
(3,370,325)
(856,590)
(1,529,790)
Cash from financing activities
(2,058,766)
(407,261)
(1,270,756)
FCF
1,671,799
2,283,737
4,576,230
Balance
Cash
6,945,956
5,173,412
3,279,129
Long term investments
3,992,143
3,359,350
3,049,206
Excess cash
9,865,403
7,587,129
5,464,465
Stockholders' equity
15,395,221
13,355,120
10,466,878
Invested Capital
20,537,416
19,288,254
18,758,060
ROIC
17.32%
14.70%
11.22%
ROCE
14.29%
11.65%
10.37%
EV
Common stock shares outstanding
1,544,725
1,485,828
1,413,531
Price
29.05
9.17%
26.61
40.57%
18.93
-2.62%
Market cap
44,874,248
13.50%
39,537,892
47.76%
26,758,146
-3.74%
EV
44,623,532
42,223,771
30,818,821
EBITDA
5,642,373
4,333,232
3,756,626
EV/EBITDA
7.91
9.74
8.20
Interest
370,709
473,710
518,336
Interest/NOPBT
8.46%
14.99%
20.42%